Unilife is a U.S. based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for our products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. All of our syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. We are ISO 13485 certified and have FDA-registered medical device manufacturing facilities in Pennsylvania. Our main product is the UnifillTM ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with their injectable drugs and vaccines. We have a strategic partnership with sanofi-aventis, who has the exclusive right to negotiate for the purchase of the Unifill syringe and is funding our industrialization program. In addition, we have retained the right to negotiate with other pharmaceutical companies seeking to utilize the Unifill syringe with drugs and vaccines marketed in therapeutic areas outside of those secured exclusively by sanofi-aventis.
Unilife Hires Intel Marketing Executive Kevin Sellers as Senior Vice President of Marketing and Communications
Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced the appointment of Kevin Sellers, a veteran marketing and communications executive at Intel Corporation, to the post of Senior Vice President, Marketing and...
Unilife Signs Long-Term Commercial Supply Agreement for Use of Depot-ject™ Delivery System with Approved Ocular Injection Drug
Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer and supplier of injectable drug delivery systems, announced today the signing of a worldwide 10 year Commercial Supply Agreement with a global pharmaceutical company for the use of the Depot-ject™...
Unilife says its 15 year-wearable injector supply deal with Sanofi is “unprecendented” and could result in over $1bn of sales annually for the delivery device maker. http://www.in-pharmatechnologist.com/Drug-Delivery/Sanofi-wearable-injectable-deal-could-net-Unilife-over-1bn-per-year
Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced that it has submitted for filing its 10-Q report for the first quarter of Fiscal Year 2015 ending September...